Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02691611 · ClinicalTrials.gov registry record
Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency
A clinical trial, sponsored by National Jewish Health.
- Completed
- Registry status
- 39
- Enrollment target
NCT02691611 is a clinical trial that has completed, run by National Jewish Health. The registered enrollment target is 39 participants.
The verdict
NCT02691611 has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 39 participants
- Enrollment target
Study Summary
The investigators hypothesize that environmentally influenced histone modifications regulate AM mediated inflammation, contributing to a variable clinical course of AATD, and may also influence or be influenced by the activity of AAT augmentation therapy.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2015-12 |
| Est. Completion | 2020-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02691611
The ClinicalTrials.gov registry entry for NCT02691611 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Jewish Health, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02691611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02691611 about?
NCT02691611 is a clinical study titled "Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency". The investigators hypothesize that environmentally influenced histone modifications regulate AM mediated inflammation, contributing to a variable clinical course of AATD, and may also influence or be influenced by the activity of AAT augmentation therapy.
What is the current status of trial NCT02691611?
This trial is currently completed. The enrollment target is 39 participants. The study started on 2015-12. Estimated completion is 2020-07.
Who is sponsoring clinical trial NCT02691611?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.